Bay Area Lyme Ventures Invests in Galaxy Diagnostics to Advance Tick-Borne Disease Testing
Bay Area Lyme Ventures has made a strategic investment in Galaxy Diagnostics to enhance the testing of tick-borne diseases, highlighting the urgent need for improved diagnostic tools as cases have increased significantly in the U.S. over the past two decades. Galaxy Diagnostics aims to fill critical gaps in the detection of complex infections associated with Lyme and other vector-borne diseases through advanced molecular testing and collaborations. The funding will help accelerate the development and accessibility of innovative testing solutions.
Partnership Aims to Accelerate Innovation in Diagnostic Tools for Patients with Complex Tick and Vector-Borne Illnesses
Partnership Aims to Accelerate Innovation in Diagnostic Tools for Patients with Complex Tick and Vector-Borne Illnesses
